RUNX1 and myelodysplastic syndrome: Wang et al. (57) retrospectively analyzed 103 patients with high-risk MDS and found that the rate of RUNX1 mutation was 18.9%, and that after treatment with VEN in combination with HMAs, the 12-month median follow-up and composite CRR were 65 and 52%, respectively, in a median of 13.5 months, month overall survival and composite CRR were 65.8 and 52.9%, respectively.